Genmab A/S (CPH:GMAB)
1,588.00
-24.50 (-1.52%)
Aug 29, 2025, 4:59 PM CET
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
8.78M DKK
Profits / Employee
3.30M DKK
Market Cap
97.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,682 | 478 | 21.69% |
Dec 31, 2023 | 2,204 | 544 | 32.77% |
Dec 31, 2022 | 1,660 | 448 | 36.96% |
Dec 31, 2021 | 1,212 | 431 | 55.19% |
Dec 31, 2020 | 781 | 233 | 42.52% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Novo Nordisk | 77,349 |
Coloplast | 16,639 |
Demant | 22,639 |
ALK-Abelló | 2,753 |
H. Lundbeck | 5,707 |
Zealand Pharma | 335 |
Ambu A/S | 5,196 |
Bavarian Nordic | 1,605 |
Genmab News
- 3 days ago - Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 4 days ago - Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - GlobeNewsWire
- 4 days ago - Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC) - Business Wire
- 17 days ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 21 days ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
- 21 days ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
- 22 days ago - Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Genmab A/S 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha